Suppr超能文献

中低收入国家哮喘诊断和管理的临床标准。

Clinical standards for the diagnosis and management of asthma in low- and middle-income countries.

机构信息

Academic Unit of Primary Care, University of Sheffield, Sheffield.

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.

出版信息

Int J Tuberc Lung Dis. 2023 Sep 1;27(9):658-667. doi: 10.5588/ijtld.23.0203.

Abstract

The aim of these clinical standards is to aid the diagnosis and management of asthma in low-resource settings in low- and middle-income countries (LMICs). A panel of 52 experts in the field of asthma in LMICs participated in a two-stage Delphi process to establish and reach a consensus on the clinical standards. Eighteen clinical standards were defined: Standard 1, Every individual with symptoms and signs compatible with asthma should undergo a clinical assessment; Standard 2, In individuals (>6 years) with a clinical assessment supportive of a diagnosis of asthma, a hand-held spirometry measurement should be used to confirm variable expiratory airflow limitation by demonstrating an acute response to a bronchodilator; Standard 3, Pre- and post-bronchodilator spirometry should be performed in individuals (>6 years) to support diagnosis before treatment is commenced if there is diagnostic uncertainty; Standard 4, Individuals with an acute exacerbation of asthma and clinical signs of hypoxaemia or increased work of breathing should be given supplementary oxygen to maintain saturation at 94-98%; Standard 5, Inhaled short-acting beta-2 agonists (SABAs) should be used as an emergency reliever in individuals with asthma via an appropriate spacer device for metered-dose inhalers; Standard 6, Short-course oral corticosteroids should be administered in appropriate doses to individuals having moderate to severe acute asthma exacerbations (minimum 3-5 days); Standard 7, Individuals having a severe asthma exacerbation should receive emergency care, including oxygen therapy, systemic corticosteroids, inhaled bronchodilators (e.g., salbutamol with or without ipratropium bromide) and a single dose of intravenous magnesium sulphate should be considered; Standard 8, All individuals with asthma should receive education about asthma and a personalised action plan; Standard 9, Inhaled medications (excluding dry-powder devices) should be administered via an appropriate spacer device in both adults and children. Children aged 0-3 years will require the spacer to be coupled to a face mask; Standard 10, Children aged <5 years with asthma should receive a SABA as-needed at step 1 and an inhaled corticosteroid (ICS) to cover periods of wheezing due to respiratory viral infections, and SABA as-needed and daily ICS from step 2 upwards; Standard 11, Children aged 6-11 years with asthma should receive an ICS taken whenever an inhaled SABA is used; Standard 12, All adolescents aged 12-18 years and adults with asthma should receive a combination inhaler (ICS and rapid onset of action long-acting beta-agonist [LABA] such as budesonide-formoterol), where available, to be used either as-needed (for mild asthma) or as both maintenance and reliever therapy, for moderate to severe asthma; Standard 13, Inhaled SABA alone for the management of patients aged >12 years is not recommended as it is associated with increased risk of morbidity and mortality. It should only be used where there is no access to ICS.The following standards (14-18) are for settings where there is no access to inhaled medicines. Standard 14, Patients without access to corticosteroids should be provided with a single short course of emergency oral prednisolone; Standard 15, Oral SABA for symptomatic relief should be used only if no inhaled SABA is available. Adjust to the individual's lowest beneficial dose to minimise adverse effects; Standard 16, Oral leukotriene receptor antagonists (LTRA) can be used as a preventive medication and is preferable to the use of long-term oral systemic corticosteroids; Standard 17, In exceptional circumstances, when there is a high risk of mortality from exacerbations, low-dose oral prednisolone daily or on alternate days may be considered on a case-by-case basis; Standard 18. Oral theophylline should be restricted for use in situations where it is the only bronchodilator treatment option available. These first consensus-based clinical standards for asthma management in LMICs are intended to help clinicians provide the most effective care for people in resource-limited settings.

摘要

这些临床标准旨在帮助中低收入国家(LMICs)资源有限环境下的医生诊断和管理哮喘。一个由 52 名哮喘领域专家组成的小组参与了两阶段 Delphi 流程,以建立和达成临床标准的共识。定义了 18 项临床标准:标准 1,对于有与哮喘相符的症状和体征的个体,应进行临床评估;标准 2,对于临床评估支持哮喘诊断的个体(年龄>6 岁),应使用手持式肺活量计测量,以证明急性支气管扩张剂反应来确认可变呼气气流受限;标准 3,如果诊断不确定,在开始治疗前应在个体(年龄>6 岁)中进行支气管扩张剂前后的肺活量测量以支持诊断;标准 4,对于有哮喘急性加重且有低氧血症或呼吸功增加的临床体征的个体,应给予补充氧气以维持饱和度在 94-98%;标准 5,对于有哮喘的个体,应通过合适的计量吸入器喷雾器设备使用短效β-2 激动剂(SABA)作为急救缓解药物;标准 6,对于有中度至重度急性哮喘加重的个体,应给予短程口服皮质激素适当剂量;标准 7,对于有严重哮喘加重的个体,应给予紧急护理,包括氧疗、全身皮质激素、吸入性支气管扩张剂(如沙丁胺醇联合或不联合异丙托溴铵)和考虑单次静脉注射硫酸镁;标准 8,所有有哮喘的个体都应接受哮喘教育和个性化行动计划;标准 9,在成人和儿童中,吸入药物(干粉装置除外)应通过合适的喷雾器设备给药。0-3 岁的儿童将需要将喷雾器与面罩连接;标准 10,年龄<5 岁有哮喘的儿童应在第 1 步按需使用 SABA,在呼吸道病毒感染引起喘息期间应使用吸入皮质激素(ICS),并从第 2 步起按需使用 SABA 和每日 ICS;标准 11,年龄 6-11 岁有哮喘的儿童应在每次使用吸入性 SABA 时使用 ICS;标准 12,所有 12-18 岁的青少年和有哮喘的成年人都应使用组合吸入器(ICS 和快速起效的长效β-激动剂[LABA],如布地奈德-福莫特罗),如有必要,按需使用(用于轻度哮喘)或作为维持和缓解治疗,用于中重度哮喘;标准 13,对于>12 岁的患者,单独使用吸入性 SABA 不推荐用于管理,因为它与更高的发病率和死亡率风险相关。仅在无法获得 ICS 时才应使用;标准 14,对于无法获得皮质激素的患者,应提供单次短期紧急口服泼尼松龙;标准 15,仅在没有吸入性 SABA 时,才应使用口服 SABA 缓解症状。调整至个体最低有效剂量以最大程度减少不良反应;标准 16,口服白三烯受体拮抗剂(LTRA)可作为预防药物,优于长期口服全身皮质激素;标准 17,在特殊情况下,如果有因加重而死亡的高风险,可考虑在个案基础上每日或隔日低剂量口服泼尼松龙;标准 18. 口服茶碱应仅限于唯一的支气管扩张剂治疗选择的情况下使用。这些是中低收入国家哮喘管理的第一个基于共识的临床标准,旨在帮助临床医生为资源有限环境下的患者提供最有效的护理。

相似文献

3
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].[支气管哮喘防治指南(2024年版)]
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.

引用本文的文献

6
Standards for clinical trials for treating TB.治疗结核病的临床试验标准。
Int J Tuberc Lung Dis. 2023 Dec 1;27(12):885-898. doi: 10.5588/ijtld.23.0341.

本文引用的文献

4
The Global Asthma Report 2022.《2022年全球哮喘报告》
Int J Tuberc Lung Dis. 2022 Nov 25;26(Supp 1):1-104. doi: 10.5588/ijtld.22.1010.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验